English

APTEVO THERAPEUTICS INC.

EDGAR

APVO Current report (8-K) · filed 2026-10-26

152 filing records in this dataset, filed from 2016-07-15 to 2026-10-26. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2022 Q4 · USD

Exact inputs and evidence

Revenue: 3114000 USD Source
Revenue: 3114000 USD Source

Operating cash flow

-5.94 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -21022000 USD Source
Operating Cash Flow: -15083000 USD Source

Free cash flow

-5.94 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -21022000 USD Source
Operating Cash Flow: -15083000 USD Source
Capital Expenditure: 29000 USD Source
Capital Expenditure: 29000 USD Source

Cash and cash equivalents: 9.8 million USD 2026-06-30 Source
Exact value

9797000 USD
Long-term debt including current maturities: 0 USD 2023-12-31 Source
Exact value

0 USD
Shares outstanding: 1.42 million shares 2026-06-30 Source
Exact value

1418952 shares

Reported share-count change

-55.99% · -1.81 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3224156 shares · 2025-06-30· Source
1418952 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

3.11 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Revenue: 3114000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 3114000 USD · 2022-01-01 – 2022-06-30 Source
Revenue: 3114000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 3114000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 3114000 USD · 2022-01-01 – 2022-06-30 Source
Revenue: 3114000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 3114000 USD · 2022-01-01 – 2022-09-30 Source

Net income

-26.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -7549000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -25967000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -20161000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -6697000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -6356000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2022-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2022-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2023-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 1.84 million

Prior period

−USD 24.13 million

2024-01-01 – 2024-12-31
Current period

−USD 25.97 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-25967000 − -24130000 = -1837000 USD

-24130000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-25967000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · APTEVO THERAPEUTICS INC. · 2025-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Year-over-year change in Net income: -1837000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -25967000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2161413 Filing: 000119312526126278 Input fundies:NetIncome: -24130000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2163273 Filing: 000119312526126278
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.8 million

Prior period

−USD 23.8 million

2024-01-01 – 2024-12-31
Current period

−USD 25.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-25600000 − -23800000 = -1800000 USD

-23800000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-25600000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · APTEVO THERAPEUTICS INC. · 2025-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Year-over-year change in Operating cash flow: -1800000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -25600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2166341 Filing: 000119312526126278 Input fundies:OperatingCashFlow: -23800000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2166904 Filing: 000119312526126278
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 3.11 million 100% of revenue
Operating costs Derived USD 31.76 million 1,020% of revenue
Operating income −USD 28.64 million −920% of revenue
Tax, interest and other Derived −USD 36.67 million −1,178% of revenue
Net income USD 8.03 million 258% of revenue

Cash

Operating cash flow −USD 21.02 million −675% of revenue
Capital expenditure USD 29,000 0.9% of revenue
Free cash flow Derived −USD 21.05 million −676% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,490% of revenue.
2017 Operating loss: operating costs were 468% of revenue.
2018 Operating loss: operating costs were 324% of revenue.
2019 Operating loss: operating costs were 226% of revenue.
2020 Operating loss: operating costs were 738% of revenue.
2021 Operating loss: operating costs were 274% of revenue.
2022 Operating loss: operating costs were 1,020% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	9985000	148758000 Derived	-138773000	-26358000 Derived	-112415000	-39374000 Derived	Source 2016-01-01 – 2016-12-31: 9985000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -138773000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -112415000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -36862000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2512000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	14658000	68607000 Derived	-53949000	-60922000 Derived	6973000	-42975000 Derived	Source 2017-01-01 – 2017-12-31: 14658000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -53949000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 6973000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -41573000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1402000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	23067000	74732000 Derived	-51665000	2024000 Derived	-53689000	-52398000 Derived	Source 2018-01-01 – 2018-12-31: 23067000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -51665000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -53689000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -51422000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 976000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	32424000	73386000 Derived	-40962000	-514000 Derived	-40448000	-42536000 Derived	Source 2019-01-01 – 2019-12-31: 32424000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -40962000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -40448000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -42383000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 153000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	4309000	31803000 Derived	-27494000	-9744000 Derived	-17750000	-29406000 Derived	Source 2020-01-01 – 2020-12-31: 4309000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -27494000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -17750000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -29318000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 88000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	12292000	33692000 Derived	-21400000	7057000 Derived	-28457000	-22392000 Derived	Source 2021-01-01 – 2021-12-31: 12292000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -21400000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -28457000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -21679000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 713000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	3114000	31755000 Derived	-28641000	-36668000 Derived	8027000	-21051000 Derived	Source 2022-01-01 – 2022-12-31: 3114000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -28641000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 8027000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -21022000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 29000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.1M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	33601000	Revenue: 33601000 Open source
20162016-12-31	Revenue	9985000	Revenue: 9985000 Open source
20172017-12-31	Revenue	14658000	Revenue: 14658000 Open source
20182018-12-31	Revenue	23067000	Revenue: 23067000 Open source
20192019-12-31	Revenue	32424000	Revenue: 32424000 Open source
20202020-12-31	Revenue	4309000	Revenue: 4309000 Open source
20212021-12-31	Revenue	12292000	Revenue: 12292000 Open source
20222022-12-31	Revenue	3114000	Revenue: 3114000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-74.7% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 33601000 Open source
20162016-12-31	Year over year	-70.3%	Revenue: 9985000 Open source Revenue: 33601000 Open source
20172017-12-31	Year over year	46.8%	Revenue: 14658000 Open source Revenue: 9985000 Open source
20182018-12-31	Year over year	57.4%	Revenue: 23067000 Open source Revenue: 14658000 Open source
20192019-12-31	Year over year	40.6%	Revenue: 32424000 Open source Revenue: 23067000 Open source
20202020-12-31	Year over year	-86.7%	Revenue: 4309000 Open source Revenue: 32424000 Open source
20212021-12-31	Year over year	185.3%	Revenue: 12292000 Open source Revenue: 4309000 Open source
20222022-12-31	Year over year	-74.7%	Revenue: 3114000 Open source Revenue: 12292000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -919.7% 2022

Net margin 257.8% 2022

Free cash flow margin -676% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-181.8%	Operating Income: -61100000 Open source Revenue: 33601000 Open source
20162016-12-31	Operating margin	-1,389.8%	Operating Income: -138773000 Open source Revenue: 9985000 Open source
20172017-12-31	Operating margin	-368.1%	Operating Income: -53949000 Open source Revenue: 14658000 Open source
20182018-12-31	Operating margin	-224%	Operating Income: -51665000 Open source Revenue: 23067000 Open source
20192019-12-31	Operating margin	-126.3%	Operating Income: -40962000 Open source Revenue: 32424000 Open source
20202020-12-31	Operating margin	-638.1%	Operating Income: -27494000 Open source Revenue: 4309000 Open source
20212021-12-31	Operating margin	-174.1%	Operating Income: -21400000 Open source Revenue: 12292000 Open source
20222022-12-31	Operating margin	-919.7%	Operating Income: -28641000 Open source Revenue: 3114000 Open source
20152015-12-31	Net margin	-176.5%	Net Income: -59317000 Open source Revenue: 33601000 Open source
20162016-12-31	Net margin	-1,125.8%	Net Income: -112415000 Open source Revenue: 9985000 Open source
20172017-12-31	Net margin	47.6%	Net Income: 6973000 Open source Revenue: 14658000 Open source
20182018-12-31	Net margin	-232.8%	Net Income: -53689000 Open source Revenue: 23067000 Open source
20192019-12-31	Net margin	-124.7%	Net Income: -40448000 Open source Revenue: 32424000 Open source
20202020-12-31	Net margin	-411.9%	Net Income: -17750000 Open source Revenue: 4309000 Open source
20212021-12-31	Net margin	-231.5%	Net Income: -28457000 Open source Revenue: 12292000 Open source
20222022-12-31	Net margin	257.8%	Net Income: 8027000 Open source Revenue: 3114000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 33601000 Open source
20162016-12-31	Free cash flow margin	-394.3%	Revenue: 9985000 Open source Operating Cash Flow: -36862000 Open source Capital Expenditure: 2512000 Open source
20172017-12-31	Free cash flow margin	-293.2%	Revenue: 14658000 Open source Operating Cash Flow: -41573000 Open source Capital Expenditure: 1402000 Open source
20182018-12-31	Free cash flow margin	-227.2%	Revenue: 23067000 Open source Operating Cash Flow: -51422000 Open source Capital Expenditure: 976000 Open source
20192019-12-31	Free cash flow margin	-131.2%	Revenue: 32424000 Open source Operating Cash Flow: -42383000 Open source Capital Expenditure: 153000 Open source
20202020-12-31	Free cash flow margin	-682.4%	Revenue: 4309000 Open source Operating Cash Flow: -29318000 Open source Capital Expenditure: 88000 Open source
20212021-12-31	Free cash flow margin	-182.2%	Revenue: 12292000 Open source Operating Cash Flow: -21679000 Open source Capital Expenditure: 713000 Open source
20222022-12-31	Free cash flow margin	-676%	Revenue: 3114000 Open source Operating Cash Flow: -21022000 Open source Capital Expenditure: 29000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -21M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-36862000	Operating Cash Flow: -36862000 Open source
20172017-12-31	Operating cash flow	-41573000	Operating Cash Flow: -41573000 Open source
20182018-12-31	Operating cash flow	-51422000	Operating Cash Flow: -51422000 Open source
20192019-12-31	Operating cash flow	-42383000	Operating Cash Flow: -42383000 Open source
20202020-12-31	Operating cash flow	-29318000	Operating Cash Flow: -29318000 Open source
20212021-12-31	Operating cash flow	-21679000	Operating Cash Flow: -21679000 Open source
20222022-12-31	Operating cash flow	-21022000	Operating Cash Flow: -21022000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -21.1M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-39374000	Operating Cash Flow: -36862000 Open source Capital Expenditure: 2512000 Open source
20172017-12-31	Free cash flow	-42975000	Operating Cash Flow: -41573000 Open source Capital Expenditure: 1402000 Open source
20182018-12-31	Free cash flow	-52398000	Operating Cash Flow: -51422000 Open source Capital Expenditure: 976000 Open source
20192019-12-31	Free cash flow	-42536000	Operating Cash Flow: -42383000 Open source Capital Expenditure: 153000 Open source
20202020-12-31	Free cash flow	-29406000	Operating Cash Flow: -29318000 Open source Capital Expenditure: 88000 Open source
20212021-12-31	Free cash flow	-22392000	Operating Cash Flow: -21679000 Open source Capital Expenditure: 713000 Open source
20222022-12-31	Free cash flow	-21051000	Operating Cash Flow: -21022000 Open source Capital Expenditure: 29000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

47.5% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	30.6%	Total Liabilities: 39149000 Open source Total Assets: 127767000 Open source
20162016-12-31	Liabilities / assets	45%	Total Liabilities: 41292000 Open source Total Assets: 91858000 Open source
20172017-12-31	Liabilities / assets	29.9%	Total Liabilities: 34972000 Open source Total Assets: 117007000 Open source
20182018-12-31	Liabilities / assets	55%	Total Liabilities: 37088000 Open source Total Assets: 67494000 Open source
20192019-12-31	Liabilities / assets	77.8%	Total Liabilities: 41566000 Open source Total Assets: 53408000 Open source
20202020-12-31	Liabilities / assets	69%	Total Liabilities: 36953000 Open source Total Assets: 53547000 Open source
20212021-12-31	Liabilities / assets	97.9%	Total Liabilities: 55385000 Open source Total Assets: 56601000 Open source
20222022-12-31	Liabilities / assets	47.5%	Total Liabilities: 16241000 Open source Total Assets: 34215000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.15× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	1.76×	Current Assets: 35134000 Open source Current Liabilities: 19943000 Open source
20162016-12-31	Current assets / current liabilities	3.65×	Current Assets: 71414000 Open source Current Liabilities: 19544000 Open source
20172017-12-31	Current assets / current liabilities	5.14×	Current Assets: 95084000 Open source Current Liabilities: 18510000 Open source
20182018-12-31	Current assets / current liabilities	2.76×	Current Assets: 48689000 Open source Current Liabilities: 17610000 Open source
20192019-12-31	Current assets / current liabilities	0.78×	Current Assets: 29995000 Open source Current Liabilities: 38239000 Open source
20202020-12-31	Current assets / current liabilities	3.25×	Current Assets: 47264000 Open source Current Liabilities: 14539000 Open source
20212021-12-31	Current assets / current liabilities	1.51×	Current Assets: 52570000 Open source Current Liabilities: 34757000 Open source
20222022-12-31	Current assets / current liabilities	3.15×	Current Assets: 27450000 Open source Current Liabilities: 8706000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 112.42 million Exact value Exact value: -112415000 USD 2016-01-01 – 2016-12-31: -112415000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2016-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -112415000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -112415000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459018005384/apvo-20171231.xml#82994 Filing: 000156459018005384 The citation records this snapshot. The page link may show a newer release later.	−USD 36.86 million Exact value Exact value: -36862000 USD 2016-01-01 – 2016-12-31: -36862000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2016-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -36862000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36862000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459018005384/apvo-20171231.xml#91629 Filing: 000156459018005384 The citation records this snapshot. The page link may show a newer release later.	USD 2.51 million Exact value Exact value: 2512000 USD 2016-01-01 – 2016-12-31: 2512000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2016-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 2512000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2512000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459018005384/apvo-20171231.xml#92517 Filing: 000156459018005384 The citation records this snapshot. The page link may show a newer release later.	−USD 39.37 million Calculation and evidence -36862000 − 2512000 USD Exact free cash flow: -39374000 USD 2016-01-01 – 2016-12-31: -36862000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2512000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2016-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -39374000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36862000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459018005384/apvo-20171231.xml#91629 Filing: 000156459018005384 Input fundies:CapitalExpenditure: 2512000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459018005384/apvo-20171231.xml#92517 Filing: 000156459018005384 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 6.97 million Exact value Exact value: 6973000 USD 2017-01-01 – 2017-12-31: 6973000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2017-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: 6973000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 6973000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459019008184/apvo-20181231.xml#101324 Filing: 000156459019008184 The citation records this snapshot. The page link may show a newer release later.	−USD 41.57 million Exact value Exact value: -41573000 USD 2017-01-01 – 2017-12-31: -41573000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2017-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -41573000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41573000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459019008184/apvo-20181231.xml#108467 Filing: 000156459019008184 The citation records this snapshot. The page link may show a newer release later.	USD 1.4 million Exact value Exact value: 1402000 USD 2017-01-01 – 2017-12-31: 1402000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2017-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 1402000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1402000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459019008184/apvo-20181231.xml#109737 Filing: 000156459019008184 The citation records this snapshot. The page link may show a newer release later.	−USD 42.98 million Calculation and evidence -41573000 − 1402000 USD Exact free cash flow: -42975000 USD 2017-01-01 – 2017-12-31: -41573000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1402000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2017-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -42975000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41573000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459019008184/apvo-20181231.xml#108467 Filing: 000156459019008184 Input fundies:CapitalExpenditure: 1402000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459019008184/apvo-20181231.xml#109737 Filing: 000156459019008184 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 53.69 million Exact value Exact value: -53689000 USD 2018-01-01 – 2018-12-31: -53689000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2018-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -53689000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53689000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459020012791/apvo-20191231.xml#119208 Filing: 000156459020012791 The citation records this snapshot. The page link may show a newer release later.	−USD 51.42 million Exact value Exact value: -51422000 USD 2018-01-01 – 2018-12-31: -51422000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2018-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -51422000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -51422000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459020012791/apvo-20191231.xml#126048 Filing: 000156459020012791 The citation records this snapshot. The page link may show a newer release later.	USD 976,000 Exact value Exact value: 976000 USD 2018-01-01 – 2018-12-31: 976000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2018-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 976000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 976000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459020012791/apvo-20191231.xml#127088 Filing: 000156459020012791 The citation records this snapshot. The page link may show a newer release later.	−USD 52.4 million Calculation and evidence -51422000 − 976000 USD Exact free cash flow: -52398000 USD 2018-01-01 – 2018-12-31: -51422000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 976000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2018-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -52398000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -51422000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459020012791/apvo-20191231.xml#126048 Filing: 000156459020012791 Input fundies:CapitalExpenditure: 976000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459020012791/apvo-20191231.xml#127088 Filing: 000156459020012791 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 40.45 million Exact value Exact value: -40448000 USD 2019-01-01 – 2019-12-31: -40448000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2019-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -40448000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40448000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459021016875/apvo-20201231.xml#111975 Filing: 000156459021016875 The citation records this snapshot. The page link may show a newer release later.	−USD 42.38 million Exact value Exact value: -42383000 USD 2019-01-01 – 2019-12-31: -42383000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2019-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -42383000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42383000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459021016875/apvo-20201231.xml#118475 Filing: 000156459021016875 The citation records this snapshot. The page link may show a newer release later.	USD 153,000 Exact value Exact value: 153000 USD 2019-01-01 – 2019-12-31: 153000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2019-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 153000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 153000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459021016875/apvo-20201231.xml#118895 Filing: 000156459021016875 The citation records this snapshot. The page link may show a newer release later.	−USD 42.54 million Calculation and evidence -42383000 − 153000 USD Exact free cash flow: -42536000 USD 2019-01-01 – 2019-12-31: -42383000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 153000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2019-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -42536000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42383000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459021016875/apvo-20201231.xml#118475 Filing: 000156459021016875 Input fundies:CapitalExpenditure: 153000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459021016875/apvo-20201231.xml#118895 Filing: 000156459021016875 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 17.75 million Exact value Exact value: -17750000 USD 2020-01-01 – 2020-12-31: -17750000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2020-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -17750000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17750000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459022011575/apvo-10k_20211231.htm#1893887 Filing: 000156459022011575 The citation records this snapshot. The page link may show a newer release later.	−USD 29.32 million Exact value Exact value: -29318000 USD 2020-01-01 – 2020-12-31: -29318000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2020-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -29318000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29318000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459022011575/apvo-10k_20211231.htm#1315962 Filing: 000156459022011575 The citation records this snapshot. The page link may show a newer release later.	USD 88,000 Exact value Exact value: 88000 USD 2020-01-01 – 2020-12-31: 88000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2020-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 88000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 88000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459022011575/apvo-10k_20211231.htm#1323581 Filing: 000156459022011575 The citation records this snapshot. The page link may show a newer release later.	−USD 29.41 million Calculation and evidence -29318000 − 88000 USD Exact free cash flow: -29406000 USD 2020-01-01 – 2020-12-31: -29318000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 88000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2020-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -29406000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29318000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459022011575/apvo-10k_20211231.htm#1315962 Filing: 000156459022011575 Input fundies:CapitalExpenditure: 88000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000156459022011575/apvo-10k_20211231.htm#1323581 Filing: 000156459022011575 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 28.46 million Exact value Exact value: -28457000 USD 2021-01-01 – 2021-12-31: -28457000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2021-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -28457000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28457000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010757/apvo-20221231.htm#2132173 Filing: 000095017023010757 The citation records this snapshot. The page link may show a newer release later.	−USD 21.68 million Exact value Exact value: -21679000 USD 2021-01-01 – 2021-12-31: -21679000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2021-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -21679000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21679000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010757/apvo-20221231.htm#1457012 Filing: 000095017023010757 The citation records this snapshot. The page link may show a newer release later.	USD 713,000 Exact value Exact value: 713000 USD 2021-01-01 – 2021-12-31: 713000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2021-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 713000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 713000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010757/apvo-20221231.htm#1465154 Filing: 000095017023010757 The citation records this snapshot. The page link may show a newer release later.	−USD 22.39 million Calculation and evidence -21679000 − 713000 USD Exact free cash flow: -22392000 USD 2021-01-01 – 2021-12-31: -21679000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 713000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2021-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -22392000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21679000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010757/apvo-20221231.htm#1457012 Filing: 000095017023010757 Input fundies:CapitalExpenditure: 713000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017023010757/apvo-20221231.htm#1465154 Filing: 000095017023010757 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 8.03 million Exact value Exact value: 8027000 USD 2022-01-01 – 2022-12-31: 8027000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2022-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: 8027000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 8027000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/apvo-20231231.htm#1528065 Filing: 000095017024025428 The citation records this snapshot. The page link may show a newer release later.	−USD 21.02 million Exact value Exact value: -21022000 USD 2022-01-01 – 2022-12-31: -21022000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2022-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -21022000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21022000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/apvo-20231231.htm#1122381 Filing: 000095017024025428 The citation records this snapshot. The page link may show a newer release later.	USD 29,000 Exact value Exact value: 29000 USD 2022-01-01 – 2022-12-31: 29000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · APTEVO THERAPEUTICS INC. · 2022-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Capital Expenditure: 29000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/apvo-20231231.htm#1127000 Filing: 000095017024025428 The citation records this snapshot. The page link may show a newer release later.	−USD 21.05 million Calculation and evidence -21022000 − 29000 USD Exact free cash flow: -21051000 USD 2022-01-01 – 2022-12-31: -21022000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 29000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · APTEVO THERAPEUTICS INC. · 2022-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Free cash flow: -21051000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21022000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/apvo-20231231.htm#1122381 Filing: 000095017024025428 Input fundies:CapitalExpenditure: 29000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025428/apvo-20231231.htm#1127000 Filing: 000095017024025428 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 17.41 million Exact value Exact value: -17411000 USD 2023-01-01 – 2023-12-31: -17411000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2023-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -17411000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17411000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017025020467/apvo-20241231.htm#2263299 Filing: 000095017025020467 The citation records this snapshot. The page link may show a newer release later.	−USD 11.7 million Exact value Exact value: -11700000 USD 2023-01-01 – 2023-12-31: -11700000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2023-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -11700000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11700000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000095017025020467/apvo-20241231.htm#2266891 Filing: 000095017025020467 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 24.13 million Exact value Exact value: -24130000 USD 2024-01-01 – 2024-12-31: -24130000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2024-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -24130000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24130000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2163273 Filing: 000119312526126278 The citation records this snapshot. The page link may show a newer release later.	−USD 23.8 million Exact value Exact value: -23800000 USD 2024-01-01 – 2024-12-31: -23800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2024-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -23800000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23800000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2166904 Filing: 000119312526126278 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 25.97 million Exact value Exact value: -25967000 USD 2025-01-01 – 2025-12-31: -25967000 USD Inspect Net Income Open source Share or cite Citation for Net Income · APTEVO THERAPEUTICS INC. · 2025-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Net Income: -25967000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25967000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2161413 Filing: 000119312526126278 The citation records this snapshot. The page link may show a newer release later.	−USD 25.6 million Exact value Exact value: -25600000 USD 2025-01-01 – 2025-12-31: -25600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · APTEVO THERAPEUTICS INC. · 2025-12-31 APTEVO THERAPEUTICS INC. (edgar:1671584) Operating Cash Flow: -25600000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T12:12:40Z Snapshot: c52b7e98830935444de7cafa8e976654198530747d6fa9e0f2397c81fa817a0c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1671584/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm#2166341 Filing: 000119312526126278 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

152 filings · 2,499 latest values · 2,499 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001671584, 1671584, APVO, edgar:1671584

Also known as APTEVO THERAPEUTICS INC., Aptevo Therapeutics Inc.

APTEVO THERAPEUTICS INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation